Search Results

Your search for Syed Ali Abutalib, MD, and Farhad Ravandi, MD,Syed Ali Abutalib, MD, and Farhad Ravandi, MD matches 2 pages

Showing 1 - 2

By Syed Ali Abutalib, MD and Farhad Ravandi, MD / November 10, 2022

Newly Diagnosed AML: Induction to Maintenance

When it is dark enough, you can see the stars.” —Ralph Waldo Emerson Low-intensity therapy for older or unfit patients with acute myeloid leukemia (AML) was introduced in the early 2000s in the form of low-dose cytarabine or hypomethylation therapy (azacitidine or decitabine). Recent studies...

leukemia

By Syed Ali Abutalib, MD, and Farhad Ravandi, MD / June 10, 2021

Update on Clinical Trials in Acute Myeloid Leukemia

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on acute myeloid leukemia (AML), such as the use of venetoclax added to...

Nov

Today In Oncology

Search Results

Your search for Syed Ali Abutalib, MD, and Farhad Ravandi, MD,Syed Ali Abutalib, MD, and Farhad Ravandi, MD matches 2 pages

Newly Diagnosed AML: Induction to Maintenance

Update on Clinical Trials in Acute Myeloid Leukemia

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC